Table 1.
Patient Characteristics
| US Cohort (n=244) | Norway Cohort (n=329) | P-value† | |
|---|---|---|---|
| Val16Ala Genotype | |||
| Val/Val | 76 (31%) | 75 (23%) | 0.060 |
| Val/Ala | 121 (50%) | 174 (53%) | |
| Ala/Ala | 47 (19%) | 80 (24%) | |
| Characteristics* | |||
| Race | |||
| African Descent | 139 (57%) | - | <0.001 |
| European Descent | 105 (43%) | 329 (100%) | |
| Age at diagnosis | |||
| (Mean ± S.D.) | 55.0 ± 13.9 | 62.5 ± 13.8 | <0.001 |
| Survival | |||
| Alive | 161 (66%) | 223 (68%) | 0.651 |
| Deceased | 83 (34%) | 106 (32%) | |
| Tumor Size | |||
| T1 | 53 (27%) | 90 (28%) | <0.001 |
| T2 | 93 (47%) | 95 (30%) | |
| T3 | 41 (21%) | 78 (24%) | |
| T4 | 10 (5%) | 56 (18%) | |
| Node Involvement | |||
| No | 141 (62%) | 136 (45%) | <0.001 |
| Yes | 85 (38%) | 167(55%) | |
| Grade | |||
| 1 | 33 (16%) | 41 (13%) | <0.001 |
| 2 | 74 (35%) | 177 (56%) | |
| 3 | 104 (49%) | 100 (31%) | |
| Estrogen Receptor Status | |||
| Negative | 100 (41%) | 96 (31%) | 0.011 |
| Positive | 143 (59%) | 216 (69%) | |
| TP53 Mutation Status | |||
| Negative | 198 (81%) | 226 (70%) | 0.002 |
| Positive | 46 (19%) | 98 (30%) | |
| Adjuvant Chemotherapy | |||
| No | 97 (43%) | 98 (27%) | <0.001 |
| Yes | 130 (57%) | 239 (73%) | |
*
Cases with missing information are not included
†
Chi-square test and Student t-test (age at diagnosis) were used to compare differences in patient characteristics